Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Declines By 40.1%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 58,800 shares, a decrease of 40.1% from the June 30th total of 98,100 shares. Currently, 1.8% of the company’s stock are sold short. Based on an average trading volume of 65,500 shares, the short-interest ratio is presently 0.9 days.

Vivos Therapeutics Trading Down 3.2 %

Shares of NASDAQ VVOS traded down $0.08 during midday trading on Friday, reaching $2.40. The company had a trading volume of 13,670 shares, compared to its average volume of 62,013. The business’s 50-day simple moving average is $2.32 and its 200 day simple moving average is $3.74. The stock has a market cap of $7.75 million, a P/E ratio of -0.22 and a beta of 7.74. Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($1.63) earnings per share for the quarter. The business had revenue of $3.42 million during the quarter. Vivos Therapeutics had a negative return on equity of 1,879.30% and a negative net margin of 117.06%.

Institutional Trading of Vivos Therapeutics

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC bought a new position in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned 4.29% of Vivos Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.